No regulatory pipeline accelerates faster than the direct threat of a lethal, uncontained pathogen.
During high-mortality epidemics, international organizations and local researchers bypass traditional administrative and logistical timelines to deploy clinical trials.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The direct threat of an expanding Ebola epidemic enabled local and global health authorities to design and launch a randomized treatment trial in just six weeks.
A rapid infestation of an animal-threatening, flesh-eating parasite triggered emergency movement controls, multi-state quarantines, and direct activation of emergency response infrastructure.
The extreme urgency of a fast-moving, high-mortality Ebola outbreak forced global health authorities to bypass Phase II trials and launch a direct Phase III trial of a cross-protective vaccine.
The urgent need to contain a fast-moving, lethal Ebola outbreak drove the immediate allocation of doses for an emergency Phase III clinical trial.
The rapid expansion of a historic Ebola outbreak forced regulators to deploy clinical trials and vaccinate healthcare workers in the field ahead of standard timelines.